Marinus Pharmaceuticals (MRNS) Failed Clinical Trial Case
$MRNS stockholder filed a claim against Marinus Pharmaceuticals for hiding the risks and potential failure of the RAISE clinical trial.
On April 15, 2024, on announcement of RAISE trial setback, $MRNS plummeted 82%, losing $341M+ in shareholder value.
Marinus investors can join this case to be notified about potential recovery.
Case Details:
On April 15, 2024, Marinus Pharmaceuticals issued a press release revealing that the RAISE trial had not met early stopping criteria and also that the Company would implement cost-saving measures.
On this news, $MRNS plummeted 82% losing $341M+ in shareholder value, and continued its decline on April 16, falling 7% and losing another $5.4M+.
On May 8, 2024, Marinus announced halting RAISE and RAISE II trials, a 20% workforce reduction, and other efficiency measures.
Moreover, Fierce Biotech reported Marinus laying off 20% of staff due to Phase 3 RAISE trial struggles.
On this news, $MRNS fell 8.91% that same day.
Based on these events, $MRNS stockholder filed a claim against Marinus and its leaders, accusing them of the following:
Marinus downplayed the risk of failing early-stopping criteria in the RAISE trial.
They also didn't disclose that failing could stop the Phase 3 RAISE II trial.
Considering all the representations, investors suspect Marinus hid the risks and potential failure of the RAISE clinical trial.